Loading
A phase 3 trial of Adagrasib, Pembrolizumab, Carboplatin, Pemetrexed and Cisplatin in non-small-cell lung cancer, run by Mirati Therapeutics Inc., now recruiting.
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) is a phase 3 interventional study registered as NCT06875310 by Mirati Therapeutics Inc., with 630 participants planned, started 2025-04-24 and due to reach its primary completion in 2029-09-07. Interventions recorded: Adagrasib, Pembrolizumab, Carboplatin, Pemetrexed, Placebo and Cisplatin.
Shares Adagrasib, KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Pemetrexed and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Pemetrexed, Cisplatin and the tag pipeline.
Shares Adagrasib, KRAS & RAS inhibitors, Pemetrexed, Bristol Myers Squibb and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab and the tag pipeline.